Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

256results about How to "High throughput" patented technology

Pipelined packet switching and queuing architecture

A pipelined linecard architecture for receiving, modifying, switching, buffering, queuing and dequeuing packets for transmission in a communications network. The linecard has two paths: the receive path, which carries packets into the switch device from the network, and the transmit path, which carries packets from the switch to the network. In the receive path, received packets are processed and switched in an asynchronous, multi-stage pipeline utilizing programmable data structures for fast table lookup and linked list traversal. The pipelined switch operates on several packets in parallel while determining each packet's routing destination. Once that determination is made, each packet is modified to contain new routing information as well as additional header data to help speed it through the switch. Each packet is then buffered and enqueued for transmission over the switching fabric to the linecard attached to the proper destination port. The destination linecard may be the same physical linecard as that receiving the inbound packet or a different physical linecard. The transmit path consists of a buffer/queuing circuit similar to that used in the receive path. Both enqueuing and dequeuing of packets is accomplished using CoS-based decision making apparatus and congestion avoidance and dequeue management hardware. The architecture of the present invention has the advantages of high throughput and the ability to rapidly implement new features and capabilities.
Owner:CISCO TECH INC

Interleaved weighted fair queuing mechanism and system

Methods and apparatus for interleaved weighted fair data packet queue sequencing are disclosed. An interleaving table specifies a queue sequence. A queue sequencer follows the table order on an epoch-by-epoch basis, selecting a queue for each epoch based on the table order. If the selected queue does not have enough data to fill its epoch, the sequencer can step to the next queue in the table order. Because the table is interleaved, higher-priority queues can be visited frequently, improving jitter and latency for packets associated with these queues. The table structure allows all queues at least some portion of the available output bandwidth, and can be organized to afford some queues a much larger portion without having those queues monopolize the output stream for inordinate amounts of time.In some embodiments, each table entry has a programmable epoch value associated with it. The epoch value can be used to weight each table entry respective to the other entries.
Owner:SILICON VALLEY BANK

Apparatus of Plural Charged-Particle Beams

A multi-beam apparatus for observing a sample with oblique illumination is proposed. In the apparatus, a new source-conversion unit changes a single electron source into a slant virtual multi-source array, a primary projection imaging system projects the array to form plural probe spots on the sample with oblique illumination, and a condenser lens adjusts the currents of the plural probe spots. In the source-conversion unit, the image-forming means not only forms the slant virtual multi-source array, but also compensates the off-axis aberrations of the plurality of probe spots. The apparatus can provide dark-field images and / or bright-field images of the sample.
Owner:ASML NETHERLANDS BV

Compositions and methods for the treatment and diagnosis of cardiovascular disease

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.
Owner:MILLENNIUM PHARMA INC +1

Integrated micro-fluidic chip for screening drug compatibility, as well as preparation method and application of integrated micro-fluidic chip

The invention relates to an integrated micro-fluidic chip for screening drug compatibility, which comprises a fluid flow passage layer, a microvalve control channel layer and a glass substrate layer, wherein the fluid flow passage layer and the microvalve control channel layer are thermally bonded through PDMS to form a fluid flow passage unit, the fluid flow passage unit and the glass substrate layer form a whole through plasma bonding, the fluid flow passage unit comprises two functional areas, namely, a medicine mixing generation area and an array cell culture area. The invention further provides a preparation method and an application of the integrated micro-fluidic chip for screening drug compatibility; an SU-8 negative photoresist technology, an AZ-XT50 positive photoresist technology, a multi-layer PDMS thermal bonding technology and a plasma bonding technology are adopted, and the micro-fluidic chip integrating functions of automatic medicine mixing and generating, cell culture, excitation, parallel analysis on compatibility results of different drugs, real-time observation and result detection is prepared, multiple experiment parameters can be obtained through once operation, and the integrated micro-fluidic chip is applied to the research on the high-flux medicine compatibility relationship.
Owner:浙江弘瑞医疗科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products